Quantum BioPharma (NASDAQ: QNTM) (CSE: QNTM) is advancing its proprietary multiple sclerosis therapy candidate, LUCID-MS, into patient-focused studies following positive Phase 1 clinical results. The company announced that Phase 1 trials in healthy volunteers demonstrated a favorable safety profile and the therapy was generally well tolerated, supporting the next stage of development.
In April 2026, Quantum BioPharma submitted an Investigational New Drug (IND) application to the U.S. Food and Drug Administration for LUCID-MS, clearing the path for a planned Phase 2 clinical trial in people living with multiple sclerosis. The therapy is designed to target demyelination and protect or restore myelin integrity, potentially offering a differentiated, first-in-class approach by directly addressing myelin loss and neurodegeneration rather than relying solely on immune modulation.
The company is also strengthening operational support for the program through a planned partnership with Allucent and engagement with neurological specialists. This news was featured in a recent article, which can be viewed at https://ibn.fm/AUhNl.
Quantum BioPharma is a biopharmaceutical company focused on building a portfolio of innovative assets for neurodegenerative and metabolic disorders, as well as alcohol misuse disorders. Through its wholly owned subsidiary, Lucid Psycheceuticals Inc., the company is developing Lucid-MS, a patented new chemical entity shown in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis.
In addition to its MS program, Quantum BioPharma invented unbuzzd and spun out its over-the-counter version to Unbuzzd Wellness Inc. (UWI), led by industry veterans. Quantum BioPharma retains a 19.84% ownership stake in UWI as of March 31, 2026, and is entitled to royalty payments of 7% of sales from unbuzzd until payments total $250 million, after which the royalty drops to 3% in perpetuity. The company retains 100% of the rights to develop similar products or alternative formulations for pharmaceutical and medical uses.
The latest news and updates regarding Quantum BioPharma are available in the company’s newsroom at https://ibn.fm/QNTM. This advancement underscores the potential for a novel therapeutic approach in multiple sclerosis, a disease affecting millions worldwide, and highlights the company's commitment to addressing unmet medical needs in neurodegenerative conditions.
